Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

49.59 +0.26 (+0.53%)
Streaming Delayed Price Updated: 3:19 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger... 
Via Benzinga
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
Shares soared and then tumbled Friday after the company offered $275 million in public shares. 
Via Investor's Business Daily
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year 
Via Talk Markets
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD 
Via Benzinga
Why NASDAQ:SNY is a Top Pick for Dividend Investors.
Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential. 
Via Chartmill
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals.
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. 
Via Chartmill
How Is The Market Feeling About Sanofi?
Via Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... 
Via Benzinga
NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
SANOFI-ADR (NASDAQ:SNY): good value for what you're paying. 
Via Chartmill
Why First Wave BioPharma Shares Are Skyrocketing Today
First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of  
Via Benzinga
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan 
Via Benzinga
European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr 
Via Benzinga
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for... 
Via Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
You can pick these players up for a great price right now. 
Via The Motley Fool
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium  
Via Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)  
Via Benzinga
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus 
Via Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM... 
Via Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.  
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.